Previous 10 | Next 10 |
SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two upcoming presentations at the 32 nd European Academy of Dermatology and Venerology (EADV) Congress...
2023-10-09 08:27:46 ET More on AnaptysBio AnaptysBio announces appointment of John Orwin as chairman of the board Seeking Alpha’s Quant Rating on AnaptysBio Historical earnings data for AnaptysBio Financial information for AnaptysBio For furthe...
Webcast at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25 SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual R&D event for the ...
53.3% of patients who received a single dose of 750mg IV imsidolimab achieved GPPPGA 0/1 (clear or almost clear) at Week 4 (primary endpoint), compared to 13.3% of patients on placebo (p=0.0131) Demonstrated favorable safety and tolerability with no SAEs, low incidence and no increase of in...
2023-09-18 16:55:05 ET More on AnaptysBio Seeking Alpha’s Quant Rating on AnaptysBio Historical earnings data for AnaptysBio Financial information for AnaptysBio AnaptysBio: Despite Early Successes, Current Situation Does Not Impress For furthe...
After more than 15 years serving on AnaptysBio’s Board of Directors, Jamie Topper, M.D., Ph.D., is stepping down and will serve as an advisor to the Board through Q1 2024 SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology c...
2023-09-15 15:00:00 ET More on the markets Key Region Of Support Sides With SPY Bullish Case Market Crosswinds And Nasdaq Looking Better Than Dow The Fed's rate-hike cycle has 'most assuredly ended' -- Lawrence Fuller Fund managers finally embrace U.S. stocks...
SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, and Dr. Paul Lizzul, chief medical officer, will...
2023-08-07 17:14:29 ET AnaptysBio press release ( NASDAQ: ANAB ): Q2 GAAP EPS of -$1.50 beats by $0.20 . Revenue of $3.46M (+183.6% Y/Y) beats by $0.69M . For further details see: AnaptysBio GAAP EPS of -$1.50 beats by $0.20, revenue of $3.46M beats by $0...
Completed enrollment of the GEMINI-1 Phase 3 trial for imsidolimab (IL-36R) in generalized pustular psoriasis (GPP) and anticipate top-line data in Q4 2023 Initiating a global Phase 2b trial for rosnilimab, a PD-1 agonist antibody, in rheumatoid arthritis (RA) later in Q3 2023 and a seco...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...
2024-05-10 18:15:02 ET Wells Fargo analyst issues BUY recommendation for ANAB on May 10, 2024 05:01PM ET. The previous analyst recommendation was Buy. ANAB was trading at $23.41 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current ana...
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colit...